Headquartered in Tempe, Align Technology, Inc. (ALGN) designs and markets Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners. With a market cap of nearly $13.6 billion, it operates through its clear aligner and imaging/CAD-CAM segments and delivers orthodontic treatments, digital scanning systems, software platforms, 3D printing solutions, and integrated services. Over the past 52 weeks, ALGN stock has fallen 4.1%, while the S&P 500 Index ($SPX) surged roughly 13%, leaving shares t ...

Core Insights - Giverny Capital Asset Management's portfolio returned 0.01% in Q4 2025, underperforming the S&P 500's 2.66% return, and YTD returns were 12.58% compared to the Index's 17.88% [1] - The firm faced challenges due to underweighting in large technology companies and overweighting in smaller niche leaders, despite strong earnings growth and capital returns from portfolio companies [1] - The market's focus on AI investments has overshadowed the actual benefits of portfolio companies, impacting overall performance [1] Company Insights - Align Technology, Inc. (NASDAQ:ALGN) was highlighted in Giverny Capital Asset Management's Q4 2025 investor letter, noting a one-month return of 5.18% but a 52-week loss of 25.10% [2] - As of January 29, 2026, Align Technology's stock closed at $164.12 per share, with a market capitalization of $11.896 billion [2] - The company is recognized for its innovative product, Invisalign clear aligners, which are expected to gradually replace traditional braces, potentially impacting the orthodontist profession [3]

Company Overview - Align Technology, Inc. (ALGN) has a market capitalization of $11.2 billion and specializes in developing and providing Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services globally [1] Financial Performance - The company is expected to announce its fiscal Q4 2025 results on February 4, with analysts predicting earnings of $2.47 per share, reflecting a 26% increase from $1.96 per share in the same quarter last year [2] - For fiscal 2025, analysts forecast an EPS of $8.18, which represents a 16.7% increase from $7.01 in fiscal 2024 [3] - Following the Q3 2025 results on October 29, ALGN shares rose by 4.9%, with adjusted EPS reported at $2.61 and revenue at $995.7 million, surpassing consensus estimates [5] Market Performance - Over the past 52 weeks, ALGN stock has declined by 22.5%, underperforming the S&P 500 Index, which rose by 16.2%, and the State Street Health Care Select Sector SPDR ETF, which returned 13.3% [4] Analyst Sentiment - The consensus rating for ALGN stock is "Moderate Buy," with 15 analysts providing coverage: eight rated it as "Strong Buy," six as "Hold," and one as "Moderate Sell" [6] - The average analyst price target for ALGN is $171.38, indicating a potential upside of 2.2% from current levels [6]

Company Overview - Align Technology, Inc. (ALGN) is based in Tempe, Arizona, and specializes in designing, manufacturing, and marketing Invisalign clear aligners and iTero intraoral scanners for orthodontists and general practitioners [1] - The company has a market capitalization of $11.4 billion, categorizing it as a large-cap stock, which reflects its significant size and influence in the medical instruments and supplies industry [2] Market Performance - ALGN's stock has experienced a decline of 33.1% from its 52-week high of $246.19, reached on December 11, 2024 [3] - Over the past three months, ALGN stock has gained 23.8%, outperforming the S&P 500 Index, which saw a gain of 5.4% during the same period [3] - In the longer term, ALGN shares have fallen 12.5% over six months and 30.6% over the past 52 weeks, significantly underperforming the S&P 500's six-month gains of 14% and 14.1% over the last year [4] Recent Financial Results - On October 29, ALGN reported its Q3 results, with an adjusted EPS of $2.61, exceeding Wall Street expectations of $2.37 [5] - The company's revenue for the quarter was $995.7 million, surpassing forecasts of $971.5 million [5] Competitive Landscape - ALGN's main competitor, DENTSPLY SIRONA Inc. (XRAY), has underperformed, with a 29% decline over six months and a 40.4% drop over the past 52 weeks [5] Analyst Sentiment - Wall Street analysts maintain a reasonably bullish outlook on ALGN, with a consensus "Moderate Buy" rating from 15 analysts [6] - The mean price target for ALGN is $174.54, indicating a potential upside of 6.1% from current price levels [6]

Core Insights - Align Technology, Inc. showcased its latest innovations in digital dentistry at the Greater New York Dental Meeting (GNYDM) 2025, emphasizing its commitment to enhancing treatment planning and patient experiences through advanced technology [1] Company Innovations - Align Technology presented the Align™ Digital Platform, which integrates software, systems, and services for a seamless workflow among doctors, labs, patients, and consumers [1] - The iTero Lumina™ scanner was highlighted for its 3x larger field of view and ability to scan 2x faster, improving efficiency in capturing complex dental cases [1] - The Align™ Oral Health Suite was introduced, featuring tools for personalized oral health reports to enhance patient engagement [1] - Invisalign Smile Architect™ software now includes Multiple Treatment Plans, allowing for side-by-side comparison of orthodontic and restorative options [1] - The iTero™ Design Suite aims to improve practice efficiency and patient experiences by streamlining the design process for in-practice 3D printing [1] - ClinCheck® Signature experience offers a faster, tailored approach to treatment planning, enhancing the overall workflow for dental professionals [1] Educational Initiatives - Align Technology sponsored clinical education sessions led by industry experts, focusing on practice productivity, diagnosis simplification, and modern patient education [1]

Core Insights - Meridian Growth Fund's third-quarter 2025 performance was negatively impacted by sector positioning and strict investment discipline, resulting in a return of -1.78% compared to the Russell 2500 Growth Index's 10.73% return [1] Company Overview: Align Technology, Inc. (NASDAQ:ALGN) - Align Technology, Inc. is a leader in dental technology, known for its Invisalign clear aligners and iTero intraoral scanners [3] - The stock experienced a one-month return of 6.25% but has lost 37.14% over the past 52 weeks, closing at $147.19 with a market capitalization of $10.669 billion on November 28, 2025 [2] Financial Performance - In Q3 2025, Align Technology reported revenue of $995.7 million, reflecting a 1.7% decline from the previous quarter but a 1.8% increase year-over-year [4] Market Dynamics - The company faced challenges with demand rebound expectations not materializing, particularly in the teen segment where revenue growth slowed to 3% [3] - Market share gains reversed due to a weaker macroeconomic environment affecting discretionary dental procedures and a shift towards lower-cost alternatives [3] Investment Sentiment - Align Technology was held by 48 hedge fund portfolios at the end of Q3 2025, a decrease from 54 in the previous quarter, indicating a decline in popularity among hedge funds [4] - Despite its potential, the company is viewed as less favorable compared to certain AI stocks that are perceived to offer greater upside potential and lower downside risk [4]

Core Insights - Align Technology, Inc. has a market capitalization of $10.2 billion and is recognized for its Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners, providing advanced orthodontic and restorative digital solutions globally [1] Stock Performance - Over the past 52 weeks, Align Technology's shares have decreased by 37.5%, underperforming the S&P 500 Index, which gained 11% during the same period [2] - Year-to-date, the stock has dropped 31.6%, while the S&P 500 has risen by 12.3% [2] Recent Financial Results - Following the Q3 2025 results released on October 29, shares surged by 4.9%, with adjusted EPS at $2.61 and revenue reaching $995.7 million, surpassing consensus estimates [4] - Align Technology raised its Q4 revenue forecast to between $1.03 billion and $1.05 billion, anticipating mid-single-digit growth in Clear Aligner volumes [4] Earnings Expectations - For the fiscal year ending December 2025, analysts project a 16.7% year-over-year increase in EPS to $8.18 [5] - The company's earnings surprise history is mixed, with two beats and two misses in the last four quarters [5] Analyst Ratings - Among 14 analysts covering Align Technology, the consensus rating is a "Moderate Buy," consisting of eight "Strong Buy" ratings, five "Holds," and one "Moderate Sell" [5] - This rating configuration is slightly less bullish than three months ago, which had nine "Strong Buy" ratings [6] Price Targets - Evercore ISI raised its price target on Align Technology to $170, maintaining an "Outperform" rating [7] - The mean price target of $173.25 indicates a potential upside of 21.5% from the current price, while the highest target of $205 suggests a 43.8% upside [7]

Company Overview - Align Technology's shares were priced at $133.14 as of October 28, 2025, with a market capitalization of $9.65 billion [3] - The company reported trailing twelve-month (TTM) revenue of $3.96 billion and net income of $437.61 million [3] - Align Technology primarily generates revenue from Invisalign clear aligners and iTero intraoral scanners, serving orthodontists, general dentists, and dental specialists [4] Business Model - The business model is based on the sale of orthodontic treatment systems and related digital solutions, with recurring revenue from software, services, and ancillary products [4] - Align Technology operates at scale with over 21,000 employees and a diversified geographic footprint, targeting both adult and pediatric patients [5] Market Position - Despite competition, Align Technology maintains a significant market share, having shipped 647,800 cases in the third quarter, representing a 4.9% year-over-year increase [7][8] - The company is the only one allowed to market the Invisalign System, although it faces competition from companies like Angelalign Technology, which reported a 46.7% increase in global case volume in 2024 [7][8] Financial Performance - Align Technology's trailing 12-month revenue is approximately 1.2% lower than its peak in early 2022, indicating stagnation in the Invisalign business [6] - Earnings per share have decreased by 78% from a peak reached over five years ago, highlighting disappointing bottom-line performance [7] Recent Developments - Navera Investment Management Ltd. reduced its stake in Align Technology by 785,194 shares, valued at approximately $122.99 million, retaining only 2,365 shares post-sale [1][2] - As of the filing date, Align Technology's shares had underperformed the S&P 500 by 57.93 percentage points, down 38.3% over the past year [2]

Core Insights - Align Technology, Inc. is a leader in digital orthodontics and restorative dentistry, with a market capitalization of nearly $9.2 billion and a product portfolio that includes Invisalign clear aligners, iTero intraoral scanners, and exocad CAD/CAM software [1] Financial Performance - The company is expected to report a profit of $1.90 per share for Q3 fiscal 2025, representing a 12.4% year-over-year increase from $1.69 per share in the same period last year [3] - Analysts project that EPS for fiscal 2025 will rise by 15.8% year-over-year to $8.12, with an additional 8.1% increase anticipated in fiscal 2026 to $8.78 [5] Recent Challenges - Align Technology faced challenges in Q2 due to uneven patient case conversion, economic uncertainties including U.S. tariff impacts, and less accessible financing for orthodontic treatments, leading to a softer seasonal uptick in case starts [4] - The company has missed Wall Street EPS estimates in three of the past four quarters, only surpassing them once [3] Market Performance - Align Technology's shares have underperformed the broader market, declining 45.9% over the past 52 weeks and 38.3% year-to-date, while the S&P 500 Index gained 17.6% over the past year [6] - Compared to the S&P 500 Healthcare Sector SPDR, which fell 6.4% over the past 52 weeks but gained 4.1% year-to-date, Align's stock performance has been notably weaker [6] Strategic Focus - Management is implementing strategies to cut costs smartly, boost efficiency, and ensure long-term growth as part of their playbook for the second half of 2025 [4]

Core Insights - Align Technology's (ALGN) efforts to expand the Invisalign business are expected to drive significant growth in the coming quarters, alongside advancements in iTero intraoral scanning technology [1][9] - The company has a strong financial position with zero debt and substantial cash flow, although foreign exchange challenges pose risks to its operations [9][10] Financial Performance - Over the past year, ALGN shares have decreased by 22.2%, while the industry saw a decline of 1.6%, and the S&P 500 composite increased by 11.3% [2] - The company's market capitalization stands at $11.66 billion, with a long-term estimated earnings growth rate of 11.2%, surpassing the industry's 9.9% [2] - ALGN has consistently exceeded earnings estimates in the last four quarters, with an average surprise of 3.4% [2] Business Developments - The Invisalign portfolio is expanding, with recent approvals for the Invisalign Palatal Expander in Turkey and the introduction of the Mandibular Advancement system in multiple countries [4][5] - ALGN has strengthened partnerships with global dental service organizations to enhance digital adoption in dentistry [6] - The iTero intraoral scanners are gaining traction globally, with new restorative capabilities and software upgrades announced in the first quarter [7][9] Solvency and Cash Flow - Align Technology maintains a strong liquidity position with no debt, reporting cash and cash equivalents of $873 million in the first quarter [10] - The cumulative net cash from operating activities increased to $52.2 million compared to $28 million in the previous year [10] Market Challenges - Foreign exchange fluctuations are a significant concern, impacting revenues as a large portion is generated outside the U.S. [11] - Both business segments experienced adverse effects from unfavorable foreign exchange rates in the first quarter [11] Earnings Estimates - The Zacks Consensus Estimate for 2025 earnings per share (EPS) remains at $10.33, with revenues projected at $4.15 billion, indicating a 3.9% increase from the previous year [12]